Dr. Birendra Kumar Sah is a gastrointestinal surgeon and clinical researcher specializing in surgical oncology with over 20 years of experience. Currently serving as Consultant Surgeon and Associate Researcher at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, his research focuses on optimizing treatment protocols for gastric cancer through multicenter clinical trials. As principal investigator of the landmark DRAGON III trial, Dr. Sah compares FLOT vs. SOX neoadjuvant chemotherapy in gastric cancer patients. His research has been published in Nature Communications and has influenced regional treatment guidelines across Asia. A Fellow of the American College of Surgeons (FACS), he serves on editorial boards of Frontiers in Surgery and BMC Cancer. Dr. Sah's academic interests include surgical education and innovation. He developed a research curriculum for surgical residents covering clinical trial design and data analysis, and has mentored over 8 graduate students. His innovation, Itihaas's Omega Anastomosis, preserves natural physiology after gastrectomy and is now part of institutional teaching. His contributions have earned recognition including the Excellence in Research Award from Ruijin Hospital and Best Oral Presentation Award from the Chinese Gastric Cancer Association.
Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital
Shanghai, China